Post-Acute COVID-19 Syndrome

Infectious Diseases
1
Pipeline Programs
3
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

R
ResVerlogiXAB - Calgary
1 program
1
ApabetalonePhase 2/31 trial
Active Trials
NCT06590324Recruiting200Est. Mar 2026
M&
Merck & Co.RAHWAY, NJ
1 program
Multiple exposuresN/A1 trial
Active Trials
NCT05822193Recruiting1,694Est. Jul 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
ResVerlogiXApabetalone
Merck & Co.Multiple exposures

Clinical Trials (2)

Total enrollment: 1,894 patients across 2 trials

A Study of Apabetalone in Subjects With Long -COVID

Start: Apr 2025Est. completion: Mar 2026200 patients
Phase 2/3Recruiting
NCT05822193Merck & Co.Multiple exposures

Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil

Start: Jul 2023Est. completion: Jul 20251,694 patients
N/ARecruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,894 patients
3 companies competing in this space